Antihypertensive Drugs Metabolism: An Update to Pharmacokinetic Profiles and Computational Approaches

Abstract

Drug discovery and development is a high-risk enterprise that requires significant investments in capital, time and scientific expertise. The studies of xenobiotic metabolism remain as one of the main topics in the research and development of drugs, cosmetics and nutritional supplements. Antihypertensive drugs are used for the treatment of high blood pressure, which is one the most frequent symptoms of the patients that undergo cardiovascular diseases such as myocardial infraction and strokes. In current cardiovascular disease pharmacology, four drug clusters - Angiotensin Converting Enzyme Inhibitors, Beta-Blockers, Calcium Channel Blockers and Diuretics - cover the major therapeutic characteristics of the most antihypertensive drugs. The pharmacokinetic and specifically the metabolic profile of the antihypertensive agents are intensively studied because of the broad inter-individual variability on plasma concentrations and the diversity on the efficacy response especially due to the P450 dependent metabolic status they present. Several computational methods have been developed with the aim to: (i) model and better understand the human drug metabolism; and (ii) enhance the experimental investigation of the metabolism of small xenobiotic molecules. The main predictive tools these methods employ are rule-based approaches, quantitative structure metabolism/activity relationships and docking approaches. This review paper provides detailed metabolic profiles of the major clusters of antihypertensive agents, including their metabolites and their metabolizing enzymes, and it also provides specific information concerning the computational approaches that have been used to predict the metabolic profile of several antihypertensive drugs.

Untitled

“…[10,11] In line with this, successful prophylaxis for migraine with amlodipine has been reported. [12,13] Among psychiatric patient population, amlodipine has been studied in cocaine dependence with conflicting results.…”

Consumption Time of Captopril Influenced the Outcomes of Patients with Stage 1 Hypertension

“…Food can affect GI physiological factors such as gastric emptying time, acid secretion, blood flow, intestinal motility, bile and enzyme secretion. [8][9][10][11][12] The effectiveness of captopril was assessed by evaluating the difference (Δ) of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in mmHg units seen from the median values. We found out that the reduction of SBP in group who consumed captopril on an empty stomach and after meal was 30 mmHg and 25 mmHg, respectively (p<0.05).…”

Application of a physiologically‐based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate

“…The main Phase I metabolic route for bumetanide is oxidation of the N ‐butyl side chain forming inactive alcohol metabolites. Glucuronidation by UDP‐glucuronosyl transferase occurs prior to excretion in the urine and bile (Zisaki, Miskovic, & Hatzimanikatis, ). It has been estimated that up to 20% of the dose is excreted via the faeces (Halladay et al, ).…”